Holen Sie sich die Stockscreener-App
10.29
4.98%
0.4544
Schlusskurs vom Vortag:
$9.84
Offen:
$9.97
24-Stunden-Volumen:
321.61K
Relative Volume:
0.65
Marktkapitalisierung:
$198.93M
Einnahmen:
$1.54M
Nettoeinkommen (Verlust:
$-84.53M
KGV:
-1.7705
EPS:
-5.8145
Netto-Cashflow:
$-73.65M
1W Leistung:
+2.38%
1M Leistung:
+15.03%
6M Leistung:
+39.22%
1J Leistung:
+6.49%
1-Tages-Spanne:
$9.895
$10.38
1-Wochen-Bereich:
$9.7301
$10.75
52-Wochen-Spanne:
$7.12
$20.56
Corbus Pharmaceuticals Holdings Inc Stock (CRBP) Company Profile
Firmenname
Corbus Pharmaceuticals Holdings Inc
Sektor
Branche
Telefon
617-963-0103
Adresse
500 RIVER RIDGE DRIVE, NORWOOD, MA
Compare CRBP vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CRBP
Corbus Pharmaceuticals Holdings Inc
|
10.29 | 193.22M | 1.54M | -84.53M | -73.65M | -5.8145 |
VRTX
Vertex Pharmaceuticals Inc
|
550.71 | 139.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
841.80 | 86.57B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,049.37 | 64.62B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
149.62 | 69.62B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
209.16 | 46.01B | 742.00K | -1.37B | -1.07B | -7.0731 |
Corbus Pharmaceuticals Holdings Inc Stock (CRBP) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-30 | Fortgesetzt | B. Riley Securities | Buy |
| 2025-02-28 | Eingeleitet | William Blair | Outperform |
| 2024-12-02 | Eingeleitet | Piper Sandler | Overweight |
| 2024-07-30 | Eingeleitet | Wedbush | Outperform |
| 2024-07-22 | Fortgesetzt | H.C. Wainwright | Buy |
| 2024-06-26 | Eingeleitet | B. Riley Securities | Buy |
| 2024-06-03 | Bestätigt | Oppenheimer | Outperform |
| 2024-05-13 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2024-03-06 | Hochstufung | Jefferies | Hold → Buy |
| 2020-09-08 | Herabstufung | BTIG Research | Buy → Neutral |
| 2020-09-08 | Herabstufung | Jefferies | Buy → Hold |
| 2020-09-08 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-09-08 | Herabstufung | ROTH Capital | Buy → Neutral |
| 2020-07-07 | Eingeleitet | ROTH Capital | Buy |
| 2020-06-17 | Eingeleitet | BTIG Research | Buy |
| 2020-03-26 | Eingeleitet | Nomura | Buy |
| 2019-04-05 | Eingeleitet | Jefferies | Buy |
| 2019-03-20 | Eingeleitet | Oppenheimer | Outperform |
| 2019-01-11 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2018-12-26 | Eingeleitet | H.C. Wainwright | Buy |
| 2018-12-07 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2018-10-24 | Eingeleitet | B. Riley FBR | Buy |
| 2018-01-19 | Eingeleitet | Raymond James | Outperform |
| 2017-12-14 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2017-11-08 | Bestätigt | Noble Financial | Buy |
| 2017-09-29 | Fortgesetzt | Noble Financial | Buy |
| 2017-03-30 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2016-11-15 | Bestätigt | JMP Securities | Mkt Outperform |
| 2016-11-11 | Bestätigt | Noble Financial | Buy |
Alle ansehen
Corbus Pharmaceuticals Holdings Inc Aktie (CRBP) Neueste Nachrichten
Corbus Pharmaceuticals Holdings Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
CRBP Q2 2026 Earnings: Wider-Than-Expected Loss of $1.81 Per Share, Yet Shares Advance 3.96%Earnings Yield Spread - Vinanet
Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors on strong trading day - MarketWatch
Corbus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Corbus Pharmaceuticals (CRBP) Holds Near $10.09 as Traders Eye $10.59 ResistanceOption Breadth - Vinanet
Corbus Pharmaceuticals (CRBP) Holds Near $10 as Buyers Defend Key SupportCovered Call ETF - Vinanet
Corbus Pharmaceuticals (CRBP): Citadel entities and Kenneth Griffin disclose 1.1% stake - Stock Titan
Price-Driven Insight from (CRBP) for Rule-Based Strategy - Stock Traders Daily
Analysts Are Bullish on Top Healthcare Stocks: Aura Biosciences Inc (AURA), Corbus Pharmaceuticals (CRBP) - The Globe and Mail
Mizuho lowers Corbus Pharmaceuticals stock price target on model updates - Investing.com
Mizuho lowers Corbus Pharmaceuticals stock price target on model updates By Investing.com - Investing.com Canada
CRBP Insider Buying: Chief Business Officer Nishant Saxena Purch - GuruFocus
Mizuho Securities Maintains Corbus Pharmaceuticals(CRBP.US) With Buy Rating, Cuts Target Price to $33 - Moomoo
Corbus Pharmaceuticals (NASDAQ:CRBP) Insider Buys 2,600 Shares of Stock - MarketBeat
Corbus Pharmaceuticals Holdings Inc. stock underperforms Wednesday when compared to competitors despite daily gains - MarketWatch
Corbus Chief Business Officer Nishant Saxena acquires 2,600 shares worth $25,037.44 - Bitget
Research Analysts Set Expectations for CRBP Q3 Earnings - MarketBeat
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Corbus Pharmaceuticals Holdings Inc. stock underperforms Monday when compared to competitors - MarketWatch
Corbus Pharmaceuticals (NASDAQ:CRBP) CEO Yuval Cohen Sells 17,000 Shares of Stock - MarketBeat
Sean Moran Sells 12,000 Shares of Corbus Pharmaceuticals (NASDAQ:CRBP) Stock - MarketBeat
Corbus Pharmaceuticals Holdings Inc Actuals & Estimates (NASDAQ:CRBP) - TradingView
Corbus Pharmaceuticals (NASDAQ:CRBP) Cut to "Strong Sell" at Wall Street Zen - MarketBeat
Corbus Pharmaceuticals Holdings Inc (CRBP) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Corbus Pharmaceuticals Holdings Inc (CRBP) Stock News Today - TradingKey
CRBP (NASDAQ: CRBP) insider plans 12,000-share sale via Stifel - Stock Titan
CRBP (CRBP) holder files to sell 17,000 Nasdaq-traded shares - Stock Titan
CRBP Maintained by Oppenheimer -- Price Target Lowered to $48.00 - GuruFocus
Oppenheimer Issues Pessimistic Forecast for Corbus Pharmaceuticals (NASDAQ:CRBP) Stock Price - MarketBeat
CRBP Maintained by HC Wainwright & Co. -- Price Target Lowered t - GuruFocus
Oppenheimer Adjusts PT on Corbus Pharmaceuticals to $48 From $52, Maintains Outperform Rating - marketscreener.com
H.C. Wainwright Maintains Corbus Pharmaceuticals(CRBP.US) With Buy Rating, Maintains Target Price $35 - Moomoo
HC Wainwright Has Lowered Expectations for Corbus Pharmaceuticals (NASDAQ:CRBP) Stock Price - MarketBeat
William Blair Maintains Corbus Pharmaceuticals(CRBP.US) With Buy Rating - Moomoo
Form 8K Corbus Pharmaceuticals Holding For: 6 August By Investing.com - Investing.com South Africa
Corbus Pharmaceuticals (NASDAQ: CRBP) ramps R&D to $51M as cash backs key trials - Stock Titan
Corbus Pharmaceuticals Holdings, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Corbus Pharmaceuticals Reports Q2 2026 Financial Results and Provides a Corporate Update - The Manila Times
Corbus Pharmaceuticals (NASDAQ: CRBP) doubles Q2 loss while securing FDA clearance for Phase 3 trial - Stock Titan
Corbus Pharmaceuticals: Q2 Earnings Snapshot - marketscreener.com
Corbus Pharmaceuticals (CRBP) Holds Gains as Biotech Momentum BuildsLow Vol ETF - Vinanet
Corbus Pharmaceuticals Announces Last Patient Last Visit In Canyon-1 Study Of CRB-913 For The Treatment Of Obesity - marketscreener.com
Corbus Pharmaceuticals (CRBP) Completes Final Patient Visit in C - GuruFocus
Corbus Pharmaceuticals (CRBP) Projected to Post Quarterly Earnings on Tuesday - MarketBeat
Corbus Pharma CMO Nicacio Leonardo Viana files initial beneficial ownership statement - Bitget
Obesity Treatment Study Reaches Final Visit; Corbus Data Expected in September - Stock Titan
CRBP Q2'26 Earnings: revenue estimate is 0 USD - TradingView
Corbus Pharmaceuticals Holdings Stock Price Forecast. Should You Buy CRBP? - StockInvest.us
Corbus Pharmaceuticals Holdings Inc expected to post a loss of $1.26 a shareEarnings Preview - TradingView
Corbus Pharmaceuticals Holdings Inc (CRBP) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Corbus Pharmaceuticals Holdings Inc. stock rises Thursday, still underperforms market - MarketWatch
Finanzdaten der Corbus Pharmaceuticals Holdings Inc-Aktie (CRBP)
Umsatz
Nettogewinn
Free Cashflow
ENV
Corbus Pharmaceuticals Holdings Inc-Aktie (CRBP) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Cohen Yuval | Chief Executive Officer |
Aug 07 '26 |
Sale |
10.08 |
17,000 |
171,396 |
157,316 |
| Moran Sean F. | Chief Financial Officer |
Aug 07 '26 |
Sale |
10.08 |
12,000 |
120,971 |
84,694 |
0.76%
1.32%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):